Results 21 to 30 of about 3,279 (167)

Development of withaferin A analogs as probes of angiogenesis [PDF]

Bioorganic & Medicinal Chemistry Letters, 2006
The natural product withaferin A (WFA) is a potent angiogenesis inhibitor and it targets the ubiquitin-proteasome pathway in vascular endothelial cells. We generated a biotinylated affinity analog WFA-LC(2)B for use as a probe to study angiogenesis.
Yasuno, Yokota, Paola, Bargagna-Mohan, Padma P, Ravindranath, Kyung B, Kim, Royce, Mohan   +4 more
openaire   +2 more sources

Molecular dynamics simulations and experimental studies reveal differential permeability of withaferin-A and withanone across the model cell membrane

Scientific Reports, 2021
Poor bioavailability due to the inability to cross the cell membrane is one of the major reasons for the failure of a drug in clinical trials. We have used molecular dynamics simulations to predict the membrane permeability of natural drugs—withanolides (
Renu Wadhwa, Neetu Singh Yadav, Shashank P. Katiyar, Tomoko Yaguchi, Chohee Lee, Hyomin Ahn, Chae-Ok Yun, Sunil C. Kaul, Durai Sundar   +8 more
doaj   +1 more source

Deciphering Antidiabetic, Anti-Inflammatory, and Anti-Cholinergic Bioactivities of Withania somnifera (L) Dunal Root Extract: An In Vitro and In Silico Investigation. [PDF]

Chem Biodivers
In this investigation, Withania somnifera root ethanol extract displays anti‐inflammatory and antidiabetic properties. Though compounds including withasomniferolide B and sitoindoside IX have been previously identified as phytoconstituents in the plant, in silico analysis from this study revealed them as new lead compounds that could act as potential ...
Mulelu L, Manjia JN, Olofinsan KA, Xulu L, Matsabisa MG.   +4 more
europepmc   +2 more sources

Withaferin A Improves Nonalcoholic Steatohepatitis in Mice [PDF]

The Journal of Pharmacology and Experimental Therapeutics, 2019
Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease that highly increases the risk of cirrhosis and liver cancer, and there are few therapeutic options available in the clinic. Withaferin A (WA), extracted from the ayurvedic medicine Withania somnifera, has a wide range of pharmacological activities; however,
Daxesh P, Patel, Tingting, Yan, Donghwan, Kim, Henrique B, Dias, Kristopher W, Krausz, Shioko, Kimura, Frank J, Gonzalez   +6 more
openaire   +2 more sources

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line [PDF]

Clinical and Molecular Hepatology, 2020
Background/Aims Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib.
Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti   +5 more
doaj   +1 more source

Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling

Journal of Ovarian Research, 2019
Background Ovarian cancer is the fifth leading cause of cancer-related deaths amongst women in the United States. Cachexia is the primary cause of death in approximately 30% of cancer patients, and is often evidenced in ovarian cancer patients. We tested
Alex R. Straughn, Sham S. Kakar
doaj   +1 more source

Withaferin A inhibits osteosarcoma cells through inactivation of Notch-1 signalling

Bangladesh Journal of Pharmacology, 2014
Human osteosarcoma cells were treated with withaferin A and the antiproliferative activity was evaluated by the 3-(4, 5 dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays.
Yang Chen, Xiang-Zhen Han, Wei Wang, Ren-Tao Zhao, Xiao Li   +4 more
doaj   +1 more source

An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines

Frontiers in Pharmacology, 2018
Pulmonary fibrosis (PF) is chronic lung disease with only two FDA approved clinically available drugs, with limited safety profile. Inadequate therapy motivated us to explore the effect of vimentin inhibitor Withaferin A, as an anti-fibrotic agent ...
Swarna Bale, Pooladanda Venkatesh, Manoj Sunkoju, Chandraiah Godugu   +3 more
doaj   +1 more source

Obesity: will withaferin win the war?

Nature Medicine, 2016
A new study shows that withaferin A, a steroidal lactone isolated from Withania somnifera, can exert profound metabolic benefits in mice, including body-weight loss, reduced hepatic steatosis and improved glucose control.
Paul T Pfluger, Matthias H Tschöp
openaire   +4 more sources

Benefits of Withania somnifera (Ashwagandha) supplementation in obesity

Journal of Education, Health and Sport, 2023
Introduction and purpose: Ashwagandha (fam. Solanaceae) also known as Withania somnifera, is an herb commonly used in traditional Ayurvedic medicine. It is sometimes called Indian ginseng or winter cherry and it is used for its extensive health benefits
Alicja Nowak, Klaudia Bogusz, Natalia Baran, Marcela Maksymowicz, Adriana Bielak, Aleksandra Nowak, Łucja Cywka, Weronika Szwed, Piotr Machowiec   +8 more
doaj   +1 more source